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ABSTRACT
What exactly makes a patient list a trade secret? This question has been a topic of heated debate for
the last thirty years. It turns out that there is no right answer to this question. Long story short: it
depends. The enumerated factors in the Uniform Trade Secrets Act (UTSA) lack specificity, and the
courts fan to clarify how to meet the UTSA’s ambiguous standards. Because there is no clear
approach to determine whether a patient list enjoys trade secret protection, there is no way for
physicians to know the proper measures to take in gathering, maintaining, and protecting patient
information. In this comment, Sara Ghantous suggests that the drafters of the UTSA should add
language that clarifies these ambiguities. In the end, despite the Act’s shortcomings, Ghantous
concludes that the courts’ various findings can serve as a guide to defining the inconsistencies of the
UTSA, and offers suggestions to aid healthcare facilities in protecting patient information.
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MAKING THE LIST: WHAT DOES IT TAKE TO MAKE A PATIENT LIST A TRADE
SECRET?
SARA GHANTOUS *
I. INTRODUCTION
“A doctor’s . . . skills encompass the ability to gather information in order to
facilitate accurate diagnosis, counsel appropriately, give therapeutic instructions, and
establish caring relationships with patients.” 1
Virtually everyone is a patient. 2 The human body is a fragile host to a variety of
needs, unique to each being. 3 The degrees of those needs vary, requiring special,
individually catered attention from physicians. The patient-physician relationship,
therefore, is a delicate one. 4
To receive the proper care we seek, we share a vast pool of information with our
physicians that is compiled in the form of patient lists. 5 This information may range
from names and contact information, 6 to x-ray films, financial records, and patient
charts. 7 Physicians generally use the information in patient lists to contact,
* © Sara Ghantous 2018.
Sara is a third year law student at The John Marshall Law
School. She is currently employed as a 711 Licensed Legal Intern at the Chicago Transit
Authority. Sara serves as the Appointed Student Liaison of the Arab American Bar Association, the
Appointed Student Representative of the John Marshall Ad Hoc Policy Committee, the Vice
President of the Middle Eastern Law Student Association, a Staff Editor on the John Marshall
Review of Intellectual Property Law, and a Candidate on the John Marshall Moot Court Honors
Program. Sara also sits on the committee of the Lebanese/Cook County Judicial Exchange Program
and recently assisted in bringing five Lebanese Judges to Chicago to expose them to various
divisions of the American judicial system.
1 See generally Jennifer Fong Ha & Nancy Longnecker, Doctor-Patient Communication: A
Review, 10 OCHSNER J. 38, 38-43 (2010) (discussing the importance of effective doctor-patient
communication in the medical field).
2 See E. Michael D. Scott, The Term “Patient” May Describe Me…But it Does Not Define Me, J.
PARTICIPANT
MED.
(December,
29
2010),
https://participatorymedicine.org/journal/opinion/commentary/2010/12/29/the-term-patient-maydescribe-me-%E2%80%A6-but-it-does-not-define-me (a patient, for the purposes of this Comment,
refers to individuals who seek healthcare services from a healthcare professional who is employed by
a covered entity).
3 Efthimios Parasidis, Defining the Essence of Being Human, 13 MINN. J.L. SCI. & TECH. 825,
834 (2012) (noting that humans contain physical, cognitive, and cultural characteristics that
distinguish them from other species, making them “uniquely human”).
4 S. Elizabeth Wilborn Malloy, Physician Restrictive Covenants: The Neglect of Incumbent
Patient Interest, 41 WAKE FOREST L. REV. 189, 235 (2003) (describing the strength of a doctorpatient bond as being “one of the most sensitive and important in American society”).
5 See James W. Lowry, Covenants Not-To-Compete in Physician Contracts: Recent Trends
Defining Reasonableness at Common Law, 24 J. LEGAL MED. 215, 232 (2003) (a physician, for the
purposes of this Comment, refers to all those licensed to practice medicine).
6 Dickinson Med. Grp., P.A. v. Foote, No. 84C-JL-22, 1989 Del. Super. LEXIS 156, at *2 (Super.
Ct. Mar. 23, 1989) (holding that the names and addresses of patients “constituted confidential and
proprietary business information protected by the Delaware Uniform Trade Secrets Act”).
7 Marsico v. Cole, C.A. No. 13104, 1995 Del. Ch. LEXIS 78, at *12 (Ch. June 30, 1995) (holding
that “[t]he patient lists of a dental practice, together with the patient histories and x-rays for each
patient, is ‘commercially valuable’ and derives independent economic value from its secrecy,”
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diagnose, treat, and gain an overall understanding of the distinctive needs unique to
each patient. Importantly, physicians need this information to communicate with
patients and provide them with the services they seek, much like your average
business. 8 This necessary information represents a valuable asset to healthcare
providers and facilities. 9 Many courts have held that the information compiled in
patient lists is so valuable that it constitutes a trade secret, entitling physicians to
But how much patient
protection from disclosure of patient information. 10
information is necessary to render a patient list a trade secret?
The purpose of this comment is to explore what exactly makes a patient list a
trade secret. In an effort to accomplish this purpose, Part I of this comment will
define relevant trade secrets law, lay-out the factors that determine whether
information is a trade secret, and explain how trade secrets become misappropriated.
Part II of this comment will briefly explain what patient lists are, and the type of
information contained in patient lists. Part III of this comment will examine
relevant cases in which courts have ruled on the issue of whether patient lists are
trade secrets. Part IV of this comment will explore what it takes to declare a patient
list a trade secret. Finally, part V of this comment will provide a conclusion that
briefly summarizes these issues, and reemphasizes their importance in the
contemporary intellectual property climate.
II. BACKGROUND
A. Defining Trade Secrets
Healthcare is an industry that furthers both commercial and humanitarian
goals, thereby requiring the protection of certain information for the growth and

representing compilations of information that meet the definition of a trade secret).
8 George A. Nation III, Non-Profit Charitable Tax-Exempt Hospitals—Wolves In Sheep’s
Clothing: To Increase Fairness and Enhance Competition in Health Care All Hospitals Should Be
For Profit Taxable, 42 RUTGERS L. J. 141, 180 (2010) (arguing that healthcare is a business because
it invokes the essence of the law of economics, comparing it to the force of gravity and the role it
plays on Earth).
9 In re Phx. Dental Sys., Inc., 144 B.R. 22, 23 (Bankr. W.D. Pa. 1992) (holding the “names of the
patients were a trade secret because they were unique” to the employer and “were not ascertainable
from an outside source.” The court also noted that the employer’s patients were its “most valuable
asset” for the following reasons: “each patient obtained services at the employer’s place of business;”
“the patient relationships were created through the efforts of the employer and were not directed to
the employee who was not entitled to benefit from that direction in trust and confidence;” and “the
employee was not able to develop patient relationships at the employer’s facility through his own
efforts because every patient was created by the employer’s special efforts to provide a treatment
facility.”).
10 Id. at 23 (stating “[i]nformation that is confidential and constitutes a valuable asset is a trade
secret for which an employer is entitled to protection from disclosure or use by former employees.
The information must be a particular secret of the employer and not a general secret of the trade
which he is engaged.”).
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success of healthcare facilities and physicians. 11 Much debate has centered on the
question of whether patient lists can be trade secrets, and numerous courts have held
that patient lists are, in fact, trade secrets, while others have disagreed. 12 After all,
patients are one of the primary sources of revenue for healthcare facilities;
consequently, physicians hold their patient lists in confidence. 13 But what exactly is
necessary to make a patient list a trade secret?
The Uniform Trade Secrets Act (“UTSA”) serves as a model for a uniform body
of state law, much like the Restatements, or the Model Rules of Professional
Responsibility. 14 It has been adopted by all but two states, including the District of
Columbia. 15 The UTSA’s multidimensional evaluation provides jurisdictions with the
opportunity to employ their own particular interpretations in determining the scope
of protections that should be granted to patient lists. 16 In doing so, the UTSA setsforth a list of definitions relating to trade secrets law. 17 The UTSA defines “trade
secret” as “information, including a formula, pattern, compilation, program device,
method, technique, or process.” 18 This information, according to the UTSA, must
possess independent economic value, and must not be “generally known to,” or
“readily ascertainable by” others who can “obtain economic value from its disclosure
or use.” 19 The UTSA further emphasizes that the information must be the “subject of
efforts that are reasonable under the circumstances to maintain its secrecy.” 20
The court in American Preferred Prescription v. Health Management broke this
definition down, defining a trade secret as a “formula, process, device or compilation
11 Don A. Hernandez & Cynthia M. Reed, Intellectual Property Issues in the Healthcare Context:
Are
Patient
Lists
Trade
Secrets?,
AMERICAN
BAR
ASSOCIATION
(Nov.
2009),
https://www.americanbar.org/newsletter/publicat
ions/aba_health_esource_home/Volume6_03_Hernandez.html (stating “[h]ealthcare is provided
by medical professionals, often for humanitarian goals. Yet, healthcare is simultaneously an
industry grappling with the same concerns of any business, including protection of valuable
intellectual property as physicians enter and leave practices in advance of their own careers.”).
12 See id. (providing a list of both federal and state cases in Delaware, Kansas, New York, and
Pennsylvania that have held that patient lists are trade secrets, using the definition of “trade
secrets” defined in the UTSA).
13 Ilg Indus. v. Scott, 273 N.E.2d 393, 396 (1971) (stating “[a] trade secret must relate to
something held in secret or confidence, and it must relate to the operation of the particular trade or
business.”).
14 Hernandez & Reed, supra note 11.
15 14 U.L.A. 541 (1985).
16 Henry J. Silberberg & Eric G. Lariere, Eroding Protection of Costumer Lists and Customer
Information Under the Uniform Trade Secrets Act, 42 BUS. LAW. 487, 487 (1987) (stating “[t]he
Uniform Trade Secrets Act represents a new statutory lens by which to view customer list and
customer information litigation.”).
17 14 U.L.A. 541.
18 Richard Stim & Stephen Fishman, The Defend Trade Secrets Act (DTSA), NDAS FOR FREE
http://www.ndasforfree.com/UTSA.html (last visited Sept. 11, 2018) (stating “[t]he Defend Trade
Secrets Act (“DTSA”), signed into law in May 11, 2016, ‘federalizes’ trade secret law by providing a
procedure for trade secret owners to file civil lawsuits in federal court.”).
19 Id. (stating “[a]ny company possessing a trade secret that is ‘related to a product or service
used in, or intended for use in, interstate or foreign commerce’ can take advantage of the provisions
of the DTSA.”).
20 Id. (The Uniform Trade Secrets Act (“UTSA”) is a model act adopted by forty-eight states and
the District of Columbia. Courts in Massachusetts and New York, the only two states that have not
adopted the UTSA, follow common law principals.).
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of information used in one’s business that confers a competitive advantage over those
in similar businesses who do not know of or use it.” 21 The court further emphasized
that a trade secret requires the composition of a “combination of characteristics and
components” individually existing in the public domain. 22 However, while the
individual components of the trade secret may be available through the public
domain, it is the combination of those individual components that comprises the
trade secret, providing businesses a unique protection and competitive advantage. 23
The UTSA lays-out a number of factors to be used in determining whether a
trade secret has been misappropriated. 24 To establish a prima facie claim for
misappropriation of trade secrets, a plaintiff must prove that: (1) a trade secret
existed; (2) the plaintiff communicated the secret to the defendant; (3) there was an
understanding that the secret would be respected; and (4) the secret information has
been improperly used by the defendant to the injury of the plaintiff. 25
B. Patient Lists: What Are They?
Finally, in order to fully understand what a patient list is, it is important to
establish what is meant by the term “patient.” For the purposes of this comment, a
patient is an individual seeking or needing healthcare-related services from a
healthcare professional. 26 Patient lists are fundamentally compilations of private
information pertaining to individual patients who seek care from a particular
physician or medical practice. 27 28 This information may include everything from a
patient’s x-rays and medical records, 29 to a patient’s name and home address. 30
186 B.R. 350, 356 (E.D.N.Y. 1995).
Id. (holding that “[a] trade secret can exist in a combination of characteristics and
components, each of which, by itself, is in the public domain, but the unified process, design and
operation of which, in unique combination, affords a competitive advantage and is a protectable
secret.”).
23 Id.
24 Richard Stim & Stephen Fishman, The Uniform Trade Secrets Act (UTSA), NDA’S FOR FREE
http://www.ndasforfree.com/UTSA.html (last visited Sept. 2018) (The UTSA sets forth definitions of
the terms: “improper means,” “misappropriation,” “person,” and “trade secret.” The UTSA further
sets forth a number of protections for those accused of trade secret theft. It also lays out a number
of protections and remedies for those who are victims of trade secret theft, like injunctive relief,
damages, awarding of attorney’s fees, and preservation of secrecy by the court.).
25 Total Care Physicians, P.A. v. O'Hara, 798 A.2d 1043, 1052 (Del. Super. Ct. 2001).
26 See generally Scott, supra note 2 (discussing the meaning of the term “patient,” and whether
the term “patient” should be replaced in order to strengthen physician-patient relationships and
improve physician-patient communication in healthcare settings).
27 Total Care Physicians, P.A., 798 A.2d at 1052 (examining whether patient information in a
medical practice will be afforded trade secret protection under Delaware’s definition of a trade
secret, which was modeled off of the UTSA).
28 Hernandez & Reed, supra note 11 (stating “[p]atient lists are natural candidates for
protection as trade secrets” because they contain patient data that is not generally available in the
public domain; they “derive economic value to the medical practices by containing valuable contact
information;” and healthcare facilities take extensive care to protect the patient information).
29 Total Care Physicians, P.A., 798 A.2d at 1053 (Comparing the content contained in
misappropriated patient lists in two precedent cases. In one case, a misappropriated patient list
contained x-ray films and patient charts. In the other, a misappropriated patient list set forth the
names and addresses of all patients treated by a particular physician. In both cases, the court
21
22
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Ultimately, patient lists are a source of great economic value to healthcare facilities
because of the private patient information that they contain. 31
C. Exploring Case Law: What Patient Information Was Used and How Was it Used?
Jurisdictions have differed considerably in their holdings regarding whether
patient lists may qualify as trade secrets. 32 The question of what exactly is required
to make a patient list a trade secret may be answered through an examination of the
relevant case law that addresses this issue. In 1987, the Supreme Court of New York
held in Allan Dampf, P. C. v. Bloom, that patient lists were, in fact, trade secrets. 33
In Dampf, the appellant, a dentist’s employee, copied and used information contained
in the appellee-employer’s electronic medical records, as well as information in
appellee’s receptionist’s desk, for the purpose of soliciting and diverting patients. 34
The patient list contained patients’ names, addresses, telephone numbers, prior and
prospective appointment dates, services provided, and fees billed. 35 The court further
found that the information in the patient list had been secured through years of
practice, individual effort, and advertising. 36 According to the court, the combination
of the effort expended and the specific type of information contained in the patient
list constituted a trade secret. 37
In contrast, however, a 1989 ruling by the Court of Special Appeals of Maryland
held in Allan M. Dworkin, D.D.S., PA. v. Blumenthal, that unrestricted patient lists
were not trade secrets. 38 In Dworkin, the appellees left the appellant’s dental
practice in order to open a competing practice, and utilized the appellant’s accessible

concluded that the patient lists were trade secrets.).
30 In re Phx. Dental Sys., Inc., 144 B.R. 22, 23 (Bankr. W.D. Pa. 1992).
31 Hernandez & Reed, supra note 11 (discussing the economic value patient lists provide to
medical practices because of the type of valuable and private information they hold, like patient
contact information, insurance information, and medical records).
32 Id. (stating “[a]lthough some jurisdictions differ, courts in four states, i.e., Delaware, Kansas,
New York, and Pennsylvania have recognized that patient lists are entitled to trade secret
protection.”).
33 127 A.D.2d 719, 720 (App. Div. 1987) (holding that the employee had “engaged in unfair
competition with the employer by his misappropriation and exploitation of confidential
information.”).
34 Id. (holding that the employee’s actions were an abuse of his trustworthy relationship with
the employer).
35 Id. (finding that the employee’s actions were an improper use of the information contained in
the patient list when it was used to solicit the employer’s patients).
36 Id. (holding that the private information contained in the patient lists was “not readily
ascertainable inasmuch as they had been obtained through past treatments” by the plaintiff and
“his judgment concerning the frequency of future checkups for each patient.” The court further noted
that the personal information of each patient had been “secured by years of efforts and advertising
by the plaintiff.”).
37 Id. (holding that the actions the plaintiff took in compiling the patient list made it a trade
secret, not only because of the private, valuable, and unique content it contained, but also because of
the time plaintiff spent, the efforts the plaintiff took, and the finances plaintiff expended to acquire
the patient-specific content. It was a combination of these factors that made the patient list a trade
secret.).
38 551 A.2d 947, 948 (1989).
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patient list in an effort to inform appellant’s patients about the new practice. 39 The
patient list included , among other things, the names and addresses of appellant’s
patients. 40 While the court recognized that patient lists may constitute a trade
secret, 41 it ultimately held that patient lists are not trade secrets when access to the
patient lists is left unrestricted and made available to the public, or to the healthcare
facility as a whole. 42 The court further noted that the facts in question demonstrated
a circumstance where an employer failed to make reasonable efforts to maintain the
secrecy of the information. Consequently, the court determined that the information
at issue should not be protected. 43
Seven years later, in American Preferred Prescription v. Health Management,
the Eastern District of New York held that an employer’s patient list that contained
the names of HIV-positive clients was a trade secret due to the confidentiality that
individuals afflicted with HIV might expect. 44 Additionally, the court addressed the
efforts that the employer took in advertising in HIV-centered publications, and the
considerable financial expenditure involved in providing support service information
to employer’s AIDS/HIV patients. 45 The court concluded that the combination of the
desired confidentiality of HIV patients, and the effort expended in acquiring the HIV
patients, qualified the employer’s patient list as a trade secret. 46
In a similar action, the Delaware Superior Court held in the 2001 case Total
Care Physicians, P.A. v. O’Hara, that patient lists were trade secrets. 47 In this case,
the defendant personally compiled a list of patients he had treated while working for
the plaintiff. 48 The defendant then sent letters to those patients announcing his
Id. (holding that the patient list was “not a trade secret because appellant had not taken
reasonable efforts to maintain its secrecy.”).
40 Id. at 950.
41 Id. (recognizing that a patient list may constitute a trade secret when certain factors are met.
These factors may include both the content contained within the patient list, like patient-specific
information, and the circumstances surrounding the preservation and secrecy of the content, like the
efforts and finances expended in obtaining the content.).
42 Id. (addressing a number of factors that may assist in determining whether a patient list is a
trade secret: “(1) the extent to which the information is known outside of the employer’s business; (2)
the extent to which it is known by the employees and others involved in the employer’s business; (3)
the extent of measures taken by the employer to guard the secrecy of the information; (4) the value
of the information to the employer and to his competitors; (5) the amount of effort or money
expended by the employer in developing the information; (6) the ease or difficulty with which the
information could be properly acquired or duplicated by others.”).
43 Id. (The court implies that patient lists, maintained with unrestricted access, do not deserve
trade secret protection because the lack of secrecy displays a lack of desire to protect the
information.).
44 186 B.R. at 356 (E.D.N.Y. 1995) (holding that the patient list was a trade secret, but denied
the employer’s request to enjoin the employee from disclosing the trade secret because the employer
failed to provide evidence that the employee disclosed or would disclose the secret information to
warrant a preliminary injunction).
45 Id. (holding an employee may not use a former employer’s customer lists to solicit customers
for the same business when those customer lists qualify as trade secrets).
46 Id. (holding an employee may not use a former employer’s customer lists to solicit customers
for the same business when those customer lists qualify as trade secrets. Patient lists may qualify as
trade secrets where the patients are “discoverable only through extraordinary efforts and the
employer’s clientele has been secured through many years’ expenditure of time and money.”).
47 798 A.2d at 1054 (Del. Super. Ct. 2001).
48 Id.
39
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departure to a new place of employment. 49 The list also contained patient charts,
addresses, medical diagnoses and treatment codes, and patient-specific insurance
information, all of which was privately maintained. 50 The court determined that the
patient list was a trade secret primarily due not only to the combination of valuable
data it contained, but also because the data in question was of the type that is
generally unavailable in the public domain. 51
Shortly after, in 2005, the Superior Court of Connecticut held in Priority Care,
Inc. v. Gentiva Heath Services that the plaintiff-employer’s patient list was not a
trade secret because it was not maintained in secrecy. 52 The patient list included
identities, diagnoses, treatment regiments, residential addresses, and other patientspecific information. 53 The court’s reasoning echoed that of the court in Dworkin.
The court concluded that while the information contained in the patient list was
valuable to competitors, valuable content alone was not enough to render the patient
list a trade secret. 54
Finally, in 2009, the U.S. District Court for the District of Kansas held in US
Bioservices Corp. v. Lugo that a patient list containing patient identities and
specifically-described patient reports was a trade secret. 55 The court further held
that, because the patient list was maintained in secrecy, and contained valuable,
patient-specific information, the list was valuable to competitors and constituted a
trade secret. 56

Id.
Id.
51 Id. (holding that the plaintiff-employer’s patient lists contained information that justifies
“trade secret status and protection” because “they compile patient addresses, medical diagnoses and
treatment codes, and specific patient information, all of which are valuable data in the commercial
operation of a medical practice, and all of which are generally unavailable in the public domain.”).
52 No. CV044002756, 2005 Conn. Super. LEXIS 23, at *16 (Super. Ct. Jan. 7, 2005) (stating
“[W]hether a particular use of a customer list by a former employee constitutes an exercise of his
right to use general knowledge and experience gained in the former employment, or whether it
violates his confidential relationship with his former employer not to use trade secrets or
confidential information acquired in the course of his former employment, will depend generally on
the particular facts and circumstances involved.” The court held, however, that there is no trade
secret “if the customers’ names can readily be ascertained through ordinary business channels.”).
53 Id. at 16-17 (holding “[W]here the identity of customers is readily ascertainable through
ordinary business channels or through classified business or trade directories, the courts refuse to
accord to the list the protection of a trade secret.” The court lays out five factors to be considered in
determining whether given information is one’s trade secret: “(1) the extent to which the information
is known outside of his business; (2) the extent to which it is known by employees and others
involved in his business; (3) the extent of measures taken by him to guard the secrecy of the
information; (4) the value of the information to him and to his competitors; (5) the amount of effort
or money expended by him in developing the information; and (6) the ease or difficulty with which
the information could be properly acquire or duplicated by others.”).
54 Id. at 18 (finding that the patient list was not maintained in secrecy because it was available
to the public domain and could, therefore, not be given trade secret protection).
55 595 F. Supp. 2d 1189, 1195 (D. Kan. 2009) (inferring that the content coupled with the
secrecy of information is what made the patient list a trade secret).
56 Id. (holding that the Kansas Trade Secrets Act, which is modeled off of the UTSA, is not
limited to the protection of customer lists, but also extends to patient lists).
49
50
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III. ANALYSIS
The case law presented suggests that there are a number of factors to consider
when determining whether a patient list deserves trade secret protection. 57 These
cases make clear that patient lists must be examined as a whole, and evaluated
using subjective, circumstantial tests to determine whether trade secret protection is
warranted. 58 Additional examination of case law is necessary in order to determine
what it takes for a patient list to qualify as a trade secret.
Recall Allan Dampf, P.C. v. Bloom, where the Supreme Court of New York
employed a broad assessment of the value of the patient information, and the efforts
that the employer had expended in obtaining it. 59 The court found that the patient
list was valuable to the employer because it contained personal and confidential
patient information that was beneficial to competitors. 60 Moreover, the court held
that the employer engaged in years of extensive effort and advertising in order to
obtain the patient information. 61 Given these facts, the court found that the
employer’s patient list was a trade secret. 62
The Dampf court failed to articulate any specific guidelines or criteria for
determining what rises to the level of sufficient value and effort. 63 An inference can
be drawn from the court’s holding that information is not “readily ascertainable” if it
is “secured through years of effort and advertising,” -meaning that information is not
generally known if substantial effort is expended to gather it. 64 The Dampf court’s
vagueness may create uncertainty for future courts when determining whether
patient lists should enjoy trade secret protection. 65
In Allan M. Dworkin, D.D.S., PA. v. Blumenthal, the Court of Special Appeals of
Maryland adopted a more stringent analysis, focusing on two factors: (1) the effort
expended in obtaining the patient information, and (2) the secrecy of the patient
57 US Bioservices Corp., 595 F. Supp. 2d at 1195; Priority Care, Inc., No. CV044002756, 2005
Conn. Super. LEXIS 23, at *16; Total Care Physicians, P.A., 798 A.2d at 1054; Am. Preferred
Prescription, 186 B.R. at 356; Allan M. Dworkin, D.D.S., PA., 551 A.2d at 948; Allan Dampf, P. C.,
127 A.D.2d at 720 (All of these cases held that valuable content alone does not award patient lists
trade secret protection. The factors the court used came from a combination of the UTSA, state
adopted versions of the UTSA, case law, circumstantial tests, and the judges’ personal discretion.).
58 Id. (The courts explored the type of data contained within the patient lists, the ways in which
the patient lists were both obtained and maintained, and the efforts expended in acquiring the
patient information. None of the courts, however, evaluated the same way. This may present a
source of confusion for cases of trade secret misappropriation, as these cases indicate that there is
not a uniform approach. Rather, these cases imply that it is up to the courts to determine what
factors to consider when assessing whether a patient list enjoys trade secret protection.).
59 127 A.D.2d at 720 (holding that the “defendant engaged in unfair competition with the
plaintiff by his misappropriation and exploitation of confidential information in abuse of his
relationship of trust with the plaintiff and his improper use of information to solicit the plaintiff’s
patients” using the information he appropriated from the plaintiff’s patient list while the plaintiff
was out of the office for a four-day vacation).
60 Id. (stating the plaintiff’s patient list contained all of the “patients’ names, addresses,
telephone numbers, dates of last appointments, and dates due for next checkup”).
61 Id. (holding that the patient information was not “readily ascertainable” because it was
“secured by years of efforts and advertising by the plaintiff[.]”).
62 Id.
63 Id.
64 Id.
65 Id.

[18:83 2018]

The John Marshall Review of Intellectual Property Law

92

list. 66 The Maryland court found that the appellant-employer did not expend enough
effort in gathering the patient information because the patient list was developed “as
an incident” to the appellant’s practice. 67 The court reasoned that while the patient
list was not available in the public domain, it was readily available and used, without
any restrictions, by others employed at the appellant’s practice. 68 Consequently, the
court found that the employer did not meet the minimum standard for secrecy
because he did not take sufficient measures to guard the secrecy of the patient list. 69
As a result, the Maryland court ultimately held that the appellant-employer’s patient
list was not eligible for protection as a trade secret. 70
The UTSA states that information warranting trade secret protection must not
be “generally known to,” or “readily ascertainable by other persons” who can “obtain
economic value from its disclosure or use.” 71 The Dworkin court adopted a more
stringent standard by expanding the definition of “other persons” to include coworkers, 72 suggesting that, in order to qualify as trade secrets, patient lists must not
be made available to the public domain, or to other employees. 73 By establishing
those rigid limitations on the sharing of patient lists within a healthcare facility, the
Dworkin court’s ruling may pose substantial challenges for both physicians and
patients. For example, this limitation might present a problem for patients who seek
immediate care and may not have the intellectual, mental, linguistic, or physical
capacity to communicate their medical histories to a substitute healthcare
professional at an urgent time – such as when a patient’s original physician may not
be readily available.
In American Preferred Prescription v. Health Management, the court primarily
evaluated the nature of the patient list information, and the efforts the plaintiffemployer expended in obtaining it. 74 The New York court concluded that the
66 551 A.2d at 951 (holding that the trial court did not err in finding that appellant’s patient list
did not constitute a trade secret).
67 Id. (stating “there is no evidence in the record to indicate that an extraordinary amount of
effort or money was expended by appellant to generate the patient list,” and “the information was
developed as an incident of the practice.”).
68 Id. (holding that the element of secrecy is essential to trade secret protection and that “access
to the patient information was totally unrestricted” and the appellant did not set any “rules,
regulations, or known procedures which restricted the availability of the patient information only to
select persons.” Therefore, “the patient information was readily available, and in fact used by, others
involved in the appellant’s practice.”).
69 Id. (holding that the “appellant took no measures to guard the secrecy of the patient list.” The
court, however, fails to define the expected secrecy standards.).
70 Id. at 950.
71 14 U.L.A. 541 (1980) (defining a trade secret as information that “derives independent
economic value, actual or potential, from not being generally known to, and not being readily
ascertainable by proper means by, other persons who can obtain economic value from its disclosure
or use”).
72 Id. (The UTSA defines “person” as a natural person, corporation, business trust, estate, trust,
partnership, association, joint venture, government, governmental subdivision or agency, or any
other legal or commercial entity.” This definition does not include the court’s interpretation of coworkers.).
73 Allan M. Dworkin, D.D.S., PA., 551 A.2d at 951.
74 186 B.R. at 356 (referencing six factors in determining whether information constitutes a
trade secret: “(1) the extent to which the information is known outside the business; (2) the extent to
which the information is known by employees and others involved in the business; (3) the extent of
measures taken by the company to guard the secrecy of the information; (4) the value of the
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employer expended a great deal of time and money in compiling a patient list that
contained AIDS/HIV specific clientele. 75 Additionally, the court found that the
employer’s patients might expect confidentiality in the information contained in the
patient list because of the sensitive nature of AIDS/HIV disease. 76 This type of
evaluation ultimately led the American Preferred court to hold that the employer’s
patient list qualified as a trade secret. 77
American courts’ historical hesitancy to address the sensitive nature of patient
list information will likely pose challenges for future litigants. 78 Under the Health
Insurance Portability and Accountability Act (“HIPPA”), all health-specific
information is legally deemed sensitive in nature. 79 The American Preferred court’s
holding essentially extends trade secret protection to almost all patient lists that
contain some sort of reference to medical histories. 80 The application of such a broad
standard could lead to an increase in the number and prevalence of
misappropriation-related lawsuits.
The Superior Court of Delaware evaluated the value and availability of an
employer’s patient list in Total Care Physicians, P.A. v. O’Hara, holding that the
plaintiff-employer’s patient list was a trade secret. 81 The Delaware Superior Court
relied on the Delaware Code’s definition of a trade secret, 82 which is ultimately
derived from the Uniform Trade Secrets Act. 83 According to the court, the facts
established that the employer’s patient list contained valuable and important patient
information that justified extending trade secret status and protection. 84 This
information included patient addresses, medical diagnoses, treatment codes, and
insurance information. 85 The Delaware court held that the patient information was
not generally available in the public domain, and was valuable to the commercial
operation of the plaintiff’s medical practice. 86 However, the court did not consider
the maintenance of the information or the efforts expended in acquiring it. 87 The
information to the company and its competitors; (5) the amount of effort and money expended by the
company in developing the information; and (6) the ease or difficulty with which the information
could be properly acquired or duplicated by others.” While the court referenced these six factors, it
primarily focused on the type of information contained in the patient list and the effort expended in
obtaining the information.).
75 Id. (holding that the plaintiff “spent a great deal of time and money to provide support service
information to its AIDS/HIV clientele” and that the plaintiff “sought out and advertised in
publications addressing HIV concerns in order to “reach the HIV community and expand its client
listing”).
76 Id. (stating “given the nature of the AID/HIV disease, it follows that individuals afflicted
might seek confidentiality and would not be accessible through ordinary channels”).
77 Id. at 357.
78 Id.
79 See generally OFFICE FOR CIVIL RIGHTS, SUMMARY OF THE HIPAA SECURITY RULE (2013)
(summarizing the purpose, elements, protected information, and safeguards of the Health Insurance
Portability and Accountability Act of 1996 (“HIPAA”)).
80 Am. Preferred Prescription, 186 B.R. at 356.
81 Total Care Physicians, P.A., 798 A.2d at 1053.
82 6 Del. C. § 2001(4) (2002).
83 14 U.L.A. 541 (1980).
84 Total Care Physicians, P.A., 798 A.2d at 1054 (holding that the patient information was
valuable and unavailable to the public domain).
85 Id.
86 Id.
87 Id. (The court does not specify how the plaintiff expended his effort to obtain the patient
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Total Care decision also failed to articulate exactly how “unavailable” the information
must be in order to meet the threshold for privacy, or how future courts should
determine what constitutes “commercially valuable” information. 88
The Total Care court’s vague explanation may be problematic for future cases
due to its lack of specificity regarding the methods by which the commercial value of
patient information is appraised. 89 Under the Delaware court’s analysis, essentially
any practice could argue that virtually any of its patient information is commercially
valuable, and, as such, is therefore entitled to trade secret protection. 90 Like
American Preferred Prescription, this reasoning could lead to an unmanageable
explosion in the number of misappropriation lawsuits filed in American courts. 91
Moreover, it has the potential to thwart industry competition by diminishing the
incentive for successful and innovative practices to make signature improvements if
they cannot make them without protection from misappropriation.
The Superior Court of Connecticut embraced a more stringent analysis in
Priority Care, Inc. v. Gentiva Health Services. 92 Instead of examining how the
plaintiff maintained the patient information, the court directed its attention to the
manner in which the plaintiff obtained the information. 93 The Connecticut court
based its finding on the confidentiality and availability of the patient information. 94
Unlike American Preferred, where the court studied the sensitive nature of the
information, 95 the Priority Care court equated the degree of confidentiality with the
availability of the patient information. 96 The Connecticut court held that the patient
list was not confidential because, even though the employer did not expose his
patient list to third parties, he obtained it through third parties who were free to
share it with others in the same industry. 97 Relevant to this analysis is the fact that
information, or the amount of money the plaintiff spent in compiling his patient list when
evaluating whether the plaintiff’s patient list permits trade secret protection. Furthermore, the
court does not discuss whether the patient information was made available to anyone else in the
plaintiff’s medical practice or if there were any restrictions, rules, or limitations set as to who can
access the patient information or when the patient information can be accessed.).
88 Id. (The court fails to set forth any rules or guidelines to aid future courts in evaluating
whether certain patient information deserves trade secret protection.).
89 Id. (The court does not break down how it reached its conclusion that the plaintiff’s patient
information retains commercial value that would benefit competitors.).
90 Id.
91 Id.; 186 B.R. at 356.
92 No. CV044002756, 2005 Conn. Super. LEXIS 23, at *17 (holding “there is no trade secret… if
the customers’ names can be readily ascertained through ordinary business channels.” The court in
this case refers to patients as customers.).
93 Id.
94 Id. (holding that the plaintiff could not “establish that the names, addresses or treatment
needs of its patients constitute either confidential information or a trade secret”).
95 Am. Preferred Prescription, 186 B.R. at 357 (The court in both of these cases focused on the
confidentiality of the patient information; however, they differ. In American Preferred Prescription,
the court focused on the sensitive, confidential nature of AIDS/HIV disease; whereas in Priority
Care, Inc., the court referred to confidentiality differently by synonymizing it with the public
availability of the information.).
96 Priority Care, Inc., No. CV044002756, 2005 Conn. Super. LEXIS 23, at *17 (The plaintiff’s
patient list consisted of the names, addresses, and treatment needs of his patients.).
97 Id. at 18 (holding that the information the plaintiff “considers to be trade secrets was actually
information provided by third parties who were free to share such information with other home
heath service providers,” including the defendants).
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the UTSA’s definition of “trade secret” does not identify how protected information
must have been obtained in order to qualify for trade secret protection. 98 Like
Dworkin, 99 the Priority Care court clarified its interpretation of the UTSA’s
definition, holding that it did not apply to information obtained through third
parties. Due to this clarification, the patient list at issue was not secret enough to
warrant protection. 100 The Superior Court of Connecticut held that because the
patient list was available to others outside of the employer’s company, it was not
secret enough to warrant trade secret protection. 101
The Priority Care court’s holding could create a myriad of issues in the field of
medical practice, such as adding new complications for transactions like hospital
mergers. 102 When hospitals merge, they both share and expand the breadth of their
consumer health market. 103 In doing so, rather than acquiring patient information
directly from the patients themselves, the hospitals retrieve patient information from
each other. 104 Under the Priority Care court’s analysis, this practice could violate the
“secrecy” standard, and prevent individual physicians from enjoying trade secret
protection for their particular patient lists. 105
Finally, in US Bioservices Corp. v. Lugo, the Kansas District Court focused on
the maintenance and economic value of a plaintiff-employers’ patient list. 106 The
court applied a traditional analysis, finding that the employers’ patient list
warranted trade secret protection. 107 The court relied on the Kansas Trade Secrets
The
Act, 108 which Kansas adopted from the Uniform Trade Secrets Act. 109
Bioservices court determined, without explanation, that the particular compilation of
14 U.L.A. 541.
Allan M. Dworkin, D.D.S., PA., 551 A.2d at 951 (expanding the UTSA’s definition of “other
persons” to include co-workers).
100 Priority Care, Inc., No. CV044002756, 2005 Conn. Super. LEXIS 23, at *17 (holding because
the plaintiff obtained the patient information through third parties, the information was thus
available to others outside of the plaintiff’s company and did not deserve trade secret protection).
101 Id.
102 See generally Gregory Curfman, Everywhere, Hospitals Are Merging — But Why Should You
Care? HARVARD HEALTH BLOG (Apr. 2015), https://www.health.harvard.edu/blog/everywherehospitals-are-merging-but-why-should-you-care-201504017844 (discussing the pros and cons of
hospital mergers).
103 Id. (stating “when individual hospitals merge into larger systems, they gain a larger share of
the consumer health market,” and discussing the financial downfalls that hospital mergers might
pose, like requiring hospitals to ask health insurance companies to pay more for medical care and
procedures).
104 Id. (stating that hospital mergers “may offer expanded access to health care services”).
105 Priority Care, Inc., No. CV044002756, 2005 Conn. Super. LEXIS 23, at *17.
106 595 F. Supp. 2d at 1195.
107 Id. (Rather than examining how the patient information was obtained, the court analyzed
how it was maintained.).
108 K.S.A. § 60-3321(4) (1988) (stating a trade secret consists of “information that ‘(i) derives
independent economic value, actual or potential, from not being generally known to, and not being
readily ascertainable by proper means by, other persons who can obtain economic value from its
disclosure or use, and (ii) is the subject of efforts that are reasonable under the circumstances to
maintain its secrecy.’” While the Kansas Trade Secrets Act enumerates a number of other factors
that may be relevant in determining whether information enjoys trade secret protection, the court
only focuses on the economic value of the patient information and the plaintiff’s maintenance of the
patient list.).
109 14 U.L.A. 541.
98
99
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the patient information made the patient list unique in nature and valuable to
competitors. 110 Moreover, the Kansas District Court ambiguously mentioned that the
employers took “reasonable efforts to maintain the secrecy” of the patient information
by only allowing access to employees during the course of their employment. 111 The
court, relying on this vaguely-articulated standard, ultimately held that the
plaintiffs’ patient list qualified as a trade secret. 112
The Bioservices court discusses how the defendants’ access to the patient lists
was limited to only the time during which they were the plaintiffs’ employees. 113
Unlike Dworkin, where the Court of Special Appeals of Maryland held that the
appellant’s patient list failed to meet the secrecy standard due to its availability to
others employed at the employer’s practice, 114 the Bioservices court held that the
employers’ patient lists met the secrecy standard despite their employees having
access to them. 115 Although the patient lists in these cases were similarly exposed,
the courts came to opposite conclusions. 116 These conflicting decisions will likely be a
source of future confusion for courts faced with determining whether a patient list,
shared throughout a healthcare facility, warrants trade secret protection.
The case law suggests that there is no uniform or clearly-defined test for
determining whether a patient list should qualify for trade secret protection. The
UTSA’s enumerated factors lack specificity, 117 and the courts have failed to articulate
how to decide whether the UTSA’s standard have been met, leaving no clear answer
as to what renders a patient list a trade secret. These ambiguities can pose a number
of challenges in the realm of commercial healthcare, ranging from the pervasive
uncertainty regarding the scope of protected information, to the actual impacts on
the individual wellbeing of patients. This Comment suggests several solutions to
these potential problems with the hope that these solutions could help alleviate the
considerable ambiguity surrounding when patient lists warrant trade secret
protection.

110 Id. (The court does not describe what made the plaintiffs’ patient list unique in nature. The
court also fails to provide any factors that could aid in determining what makes a patient list unique
in nature. The court simply synonymizes customer lists with patient lists, and briefly states that
there is a difference between patient lists that contain information concerning patients, and patient
lists that only contain the patients’ identities.).
111 Id.
112 Id. (concluding that because the plaintiffs’ patient lists contained secret, specificallydescribed patient reports, and not merely the patients’ identities, they are of economic value to
competitors and permit trade secret protection).
113 Id. at 1192 (The court fails to discuss the methods the plaintiffs practiced in maintaining the
secrecy of the patient lists. Although the court held that the patient lists were maintained in
secrecy, the court was contradictory when it failed to discuss the precautions the plaintiffs took in
maintaining the secrecy of the patient lists. Instead, the court discussed the exposure of the
plaintiffs’ patient lists throughout the healthcare facility and amongst their co-workers.).
114 Allan M. Dworkin, D.D.S., PA., 551 A.2d at 948 (For a refresher on the background of this
case, refer to pages 7-8 or 12-14.).
115 US Bioservices Corp., 595 F. Supp. 2d at 1195.
116 Id.; Allan M. Dworkin, D.D.S., PA., 551 A.2d at 948 (The court applies a restrictive analysis
in Dworkin, but a liberal one in Bioservices.).
117 14 U.L.A. 541.
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IV. PROPOSAL
Both the UTSA 118 and the existing jurisprudence 119 concerning these issues
leave a number of important questions unanswered. For example, the law does not
make clear what type or combination of patient information is more likely to warrant
trade secret protection. 120 For example, courts and physicians are left questioning
whether unidentified x-rays are commercially valuable enough to merit trade secret
protection. 121 Additionally, the law does not explain the amount of requisite effort
that should be expended in obtaining the information, 122 who the patient information
may be obtained from, 123 how valuable the patient information must be to
physicians, 124 and the scope of controls and regulations physicians must implement
in order to ensure the secrecy of the patient lists. 125 Prior case law also fails to
articulate to whom or to how many people the patient lists can have been made
available while still remaining eligible for protection. 126
The UTSA’s vague standards and the courts’ varying and ambiguous holdings
leave physicians with considerable uncertainty over the protection of their patient
lists. Due to the lack of a clear and uniform method for determining whether a
patient list should enjoy trade secret protection, there remains no way for physicians
to know the proper measures to take in gathering and maintaining patient
information. In an attempt to help remedy some of these uncertainties, this
comment offers two solutions that could be used in developing a more coherent

Id.
US Bioservices Corp., 595 F. Supp. 2d at 1195; Priority Care, Inc., No. CV044002756, 2005
Conn. Super. LEXIS 23, at *16; Total Care Physicians, P.A., 798 A.2d at 1054; Am. Preferred
Prescription, 186 B.R. at 356; Allan M. Dworkin, D.D.S., PA., 551 A.2d at 948; Allan Dampf, P. C.,
127 A.D.2d at 720 (After analyzing, comparing, and contrasting the holdings in these cases, the
question regarding what it takes for a patient list to qualify for trade secret protection still remains
unanswered. These cases suggest that it is left up to the jurisdiction of the court hearing the case to
determine whether a patient list has satisfied enough elements to qualify as a trade secret.
However, each of the cases above created its own set of elements, essentially branching out of the
requirements set out in the UTSA and expanding the list of requisites that a patient list must have
in order to enjoy trade secret protection.).
120 Am. Preferred Prescription, 186 B.R. at 356 (The court’s holding extends trade secret
protection to nearly all patient lists that contain some sort of reference to a patient’s medical
histories.).
121 Total Care Physicians, P.A., 798 A.2d at 1054 (The court lacks specificity in its evaluation of
commercially valuable information.).
122 Allan Dampf, P. C., 127 A.D.2d at 720 (The court failed to set forth any guidelines to
evaluate sufficient value and effort expended in obtaining patient information.).
123 Priority Care, Inc., No. CV044002756, 2005 Conn. Super. LEXIS 23, at *16 (Instead of
examining how the patient list was maintained, the court evaluated how the patient information
was obtained. The court’s holding suggested that patient information that is obtained through third
parties is not confidential enough to warrant a patient list trade secret protection.).
124 Total Care Physicians, P.A., 798 A.2d at 1054.
125 US Bioservices Corp., 595 F. Supp. 2d at 1195 (The court’s holding suggests that patient lists
that are made available to employees still meet the secrecy standard to permit trade secret
protection.).
126 Allan M. Dworkin, D.D.S., PA., 551 A.2d at 951 (The court’s holding suggests that patient
lists cannot be made available to the employees or co-workers, which is opposite from the holding
that the Bioservices court reached.).
118
119
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approach to future cases where the eligibility of patient lists for trade secret
protection is at issue.
First, the National Conference of Commissioners on Uniform State Laws should
add specificity to the language of the UTSA. 127 The UTSA should set-forth explicit
guidelines for states to adopt in order to aid courts in determining whether a patient
list qualifies for trade secret protection. The UTSA currently defines a trade secret
as information that “derives independent economic value . . . from not being generally
known to, and not being readily ascertainable by . . . persons who can obtain
economic value from its disclosure or use.” 128 The UTSA further states that the
information must be “the subject of efforts that are reasonable under the
circumstances to maintain its secrecy.” 129
While the UTSA briefly touches on the maintenance and value of the
information, it lacks guidelines that establish how the information must be
obtained. 130 More specifically, the UTSA neither states whether the information may
be acquired from third parties, nor discloses the amount of effort that must be
expended in gathering the information. 131 The drafting committee should add
language into the UTSA that specifically addresses these ambiguities. Therefore,
with the proposed additions, the UTSA should define trade secret protected
information as “information that (i) derives independent economic value . . . from not
being generally known to, and not being readily ascertainable by . . . persons who can
obtain economic value from its disclosure or use, (ii) is the subject of efforts that are
reasonable under the circumstances to maintain its secrecy, (iii) is obtained from
reliable sources, 132 and (iiii) is gathered through a reasonable expenditure of
effort.” 133
The proposed additional language is direct, and gives courts discretion in
determining how to satisfy the aforementioned “reasonable” and “reliable” standards.
Furthermore, the addition of elements three and four serve as a guide not only for
courts, but also for physicians and healthcare facilities to know how to obtain and
maintain valuable information.
This additional language, however, does not resolve all of the discrepancies
caused by the present state of the law. There are multiple questions that remain
unanswered, including what type of patient information that a patient list must
contain in order to qualify as “valuable” to competitors, 134 the regulations physicians
127 14 U.L.A. 541 (The UTSA was drafted by the National Conference of Commissioners on
Uniform State Laws.).
128 Id. (The UTSA explicitly states that a ‘trade secret’ is “information, including a formula,
pattern, compilation, program device, method, technique, or process, that: (i) derives independent
economic value, actual or potential, from not being generally known to, and not being readily
ascertainable by proper means by, other persons who can obtain economic value from its disclosure
or use, and (ii) is the subject of efforts that are reasonable under the circumstances to maintain its
secrecy[.]”).
129 Id.
130 Id.
131 Id.
132 Priority Care, Inc., No. CV044002756, 2005 Conn. Super. LEXIS 23, at *16.
133 Allan Dampf, P. C., 127 A.D.2d at 72.
134 Total Care Physicians, P.A., 798 A.2d at 1054 (for example, a patient list containing only the
x-rays and diagnoses of patients may not be valuable to competitors without the names or contact
information of the patients).
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must implement throughout healthcare facilities in order to maintain the secrecy of
patient lists, 135 and to whom or to how many people a patient list may be made
available and still maintain eligibility for trade secret protection. 136 It is important
to answer these questions so that physicians know how to protect their patient lists,
particularly due to the sensitive nature of the information 137 and the patient’s
expectations of confidentiality. 138
Admittedly, the proposed additional language, even if implemented into the
UTSA, 139 may not remedy all the uncertainties that remain in this area of law. The
National Conference of Commissioners on Uniform State Laws should create
additional legislation specifically addressing the trade secret protection of patient
lists. The new legislation should attempt to speak to the ambiguities created by the
courts, as well as those created by the existing language of the UTSA. To do this, the
legislation must address the following elements: (1) the combination of information
required to make the patient list commercially valuable; 140 (2) the requisite degree of
effort that must be expended in obtaining the information; 141 (3) whether the patient
list can be obtained from third parties, and if so, who those third parties may be; 142
(4) the regulations physicians must implement in order to maintain the secrecy of the
patient lists; 143 (5) and to whom the patient lists may be made available, inside and
outside of the healthcare facility, in order to remain eligible for protection. 144
Furthermore, the new legislation must remedy the remaining ambiguities by settingforth the definitions of existing terms and phrases. 145 For example, the legislation
must define the terms “reasonable,” “reliable,” “trade secret,” and “patient list.”
V. CONCLUSION
The body of existing case law that examines these complex issues makes clear
that there is currently no uniform approach to determining whether a patient list
135 US Bioservices Corp., 595 F. Supp. 2d at 1195 (for example, a physician or healthcare facility
that does not require employees to enter a password in order to access patient lists within a
computer, may or may not meet the secrecy standard if a court finds that a password is required in
order to meet the “reasonableness” standard of the UTSA).
136 Id.; Allan M. Dworkin, D.D.S., PA., 551 A.2d at 951 (The Bioservices court and the Dworkin
court reached opposite holdings regarding the sharing of patient lists throughout a healthcare
facility, leaving the question open as to how to meet the secrecy standard.).
137 See generally OFFICE FOR CIVIL RIGHTS, SUMMARY OF THE HIPAA SECURITY RULE (2013)
(suggesting that essentially all patient information is sensitive in nature under the Health
Insurance Portability and Accountability Act of 1996 (“HIPAA”)).
138 Am. Preferred Prescription, 186 B.R. at 356 (holding that an employee’s patient list
containing the names of HIV-positive clients was a trade secret because of the confidentiality that
individuals afflicted with HIV might expect).
139 14 U.L.A. 541.
140 Total Care Physicians, P.A., 798 A.2d at 1054.
141 Allan Dampf, P. C., 127 A.D.2d at 720.
142 Priority Care, Inc., No. CV044002756, 2005 Conn. Super. LEXIS 23, at *16.
143 US Bioservices Corp., 595 F. Supp. 2d at 1195.
144 Allan M. Dworkin, D.D.S., PA., 551 A.2d at 951 (placing limitations on employee access).
145 14 U.L.A. 541 (The UTSA contains a list of definitions for a number of terms and phrases
used in the Act. These terms and phrases include, “improper means,” “misappropriation,” “person,”
and “trade secret[.]”).
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qualifies for trade secret protection. 146 The diverse language used by the courts in
their analyses, 147 and the elements prescribed in the UTSA, 148 provides future courts
with little help when considering these issues. These ambiguities leave both courts
and physicians alike with numerous unanswered questions concerning the creation,
maintenance, and evaluation of patient lists.
While these questions remain unanswered, the UTSA 149 and the established
case law 150 teach us that conduct is as important as content. In other words, patient
information alone is not enough to grant a patient list trade secret protection. 151 The
measures that a physician takes to create a patient list and to maintain its secrecy
are just as important as the information contained within the patient list itself. 152
While this notion may be generally helpful, it does not address the persisting
uncertainties with which both courts and physicians continue to struggle.
This Comment proposes two legislative solutions to resolve the UTSA’s
ambiguous language, 153 and the often contradicting opinions and approaches
employed by the courts that have considered these issues in past cases. 154 First, the
National Conference of Commissioners on Uniform State Laws should adopt
language in the UTSA 155 addressing two additional elements: (1) the appropriate
sources from which patient information is to be obtained, 156 and (2) the degree of
effort that must be expended in gathering the patient information. 157
Second, legislation specific to the trade secret protection of patient lists should
be drafted and integrated. Like the amendments to the URSA, this legislation
should address the amount of effort that should be expended in obtaining patient
information, from whom the patient information can be obtained to remain “reliable”,
how valuable the patient information must be to physicians, the regulations
physicians must implement in order to maintain the secrecy of the patient lists, and
146 US Bioservices Corp., 595 F. Supp. 2d at 1195; Priority Care, Inc., No. CV044002756, 2005
Conn. Super. LEXIS 23, at *16; Total Care Physicians, P.A., 798 A.2d at 1054; Am. Preferred
Prescription, 186 B.R. at 356; Allan M. Dworkin, D.D.S., PA., 551 A.2d at 948; Allan Dampf, P. C.,
127 A.D.2d at 720.
147 Id.
148 14 U.L.A. 541.
149 Id.
150 US Bioservices Corp., 595 F. Supp. 2d at 1195; Priority Care, Inc., No. CV044002756, 2005
Conn. Super. LEXIS 23, at *16; Total Care Physicians, P.A., 798 A.2d at 1054; Am. Preferred
Prescription, 186 B.R. at 356; Allan M. Dworkin, D.D.S., PA., 551 A.2d at 948; Allan Dampf, P. C.,
127 A.D.2d at 720.
151 Id.
152 Id.
153 14 U.L.A. 541.
154 US Bioservices Corp., 595 F. Supp. 2d at 1195; Priority Care, Inc., No. CV044002756, 2005
Conn. Super. LEXIS 23, at *16; Total Care Physicians, P.A., 798 A.2d at 1054; Am. Preferred
Prescription, 186 B.R. at 356; Allan M. Dworkin, D.D.S., PA., 551 A.2d at 948; Allan Dampf, P. C.,
127 A.D.2d at 720 (Each court takes a different approach in evaluating whether a patient list enjoys
trade secret protection. These varying approaches leave physicians questioning whether they have
taken the appropriate measures to protect their patient lists, and leaves courts questioning how to
properly evaluate whether a patient list enjoys trade secret protection.).
155 14 U.L.A. 541.
156 Priority Care, Inc., No. CV044002756, 2005 Conn. Super. LEXIS 23, at *16 (holding that
patient information obtained through third parties does not meet the secrecy standard of the UTSA).
157 Allan Dampf, P. C., 127 A.D.2d at 72 (failing to define the requirements for “sufficient
effort”).
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to whom or how many people the patient lists may be made available while
continuing to remain eligible for trade secret protection.

